NleB/SseK-catalyzed arginine-glycosylation and enteropathogen virulence are finely tuned by a single variable position contiguous to the catalytic machinery.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

5 citing papers in PubMed, 5 citations in OpenAlex.

1. Mechanism of Bacterial ArginineACS catalysis · 2026
   Article
2. STD NMR Epitope Perturbation by Mutation Unveils the Mechanism of YM155 as an Arginine-Glycosyltransferases Inhibitor Effective in Treating Enteropathogenic Diseases.JACS Au · 2025
   Article
3. Speaking the host language: howMicrobiology (Reading, England) · 2023
   Review
4. Structural basis for the synthesis of the core 1 structure by C1GalT1.Nature communications · 2022
   Article
5. Arginine GlcNAcylation and Activity Regulation of PhoP by a Type III Secretion System Effector inFrontiers in microbiology · 2021
   Article

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

7 authors at 4 institutions in 4 countries.

Funding

Abstract